Differences

This shows you the differences between two versions of the page.

--- home:food:aim_health:aging [02.01.2019] – [Aging and Olmesartan] sallieq
+++ home:food:aim_health:aging [02.11.2019] – [with additional studies] sallieq
@@ Line 7: / Line 7: @@
 ===== with additional studies =====
- Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.  (({{pubmed>long:24772521}}))
- In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>long:24535009}}))
  Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed>long:24516110}}))
  The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed>long:16508590}}))
+ Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.  (({{pubmed>long:24772521}}))
 The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed>long:27082551}}))
-Therapeutic and supratherapeutic OM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}}))
+Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed>long:26239632}}))
+ In conclusion, there is no robust signal for harm with olmesartan use.  (({{pubmed>long:24535009}}))
 ==== General research on aging ====
@@ Line 110: / Line 111: @@
 === Long term treatment ===
-Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.
+ Patients receiving the highest dose of olmesartan (40 and 80 mg) had an inward carotid remodeling and were shifted toward a lower elastic modulus at a given circumferential wall stress, indicating an improvement in the intrinsic elastic properties of the carotid artery wall material. These data suggest that 40 and 80 mg olmesartan were able to significantly remodel and destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg.
 //hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint  (({{pubmed>long:25001274}}))
 {{tag>olmesartan Food_and_drink summary}}

home/food/aim_health/aging.txt · Last modified: 09.14.2022 by 127.0.0.1